Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema

British Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2010, Pages 179-186

  Bas, Murat ^d   Hoffmann, Thomas K ^a,b   Tiemann, Bernd ^a   Dao, Vu Thao Vi ^a   Bantis, Christos ^a   Balz, Vera ^a   Schultz Coulon, Hans Jürgen ^c   Stark, Thomas ^d   Schuler, Patrick ^a,b   Greve, Jens ^b   Ivens, Katrin ^a   Bier, Henning ^d   Kojda, Georg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Lukaskrankenhaus GmbH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

ACE I D polymorphism; Angio oedema; Bradykinin; Serum ACE activity

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR 2; BRADYKININ B2 RECEPTOR 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; AGE; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2; RISK FACTORS; SEX FACTORS;

EID: 75149117895     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03567.x     Document Type: Article

References (36)

1. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999 44 : 21 5.
2. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, Ewan PW. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988 260 : 967 970.
3. Weiner JM. Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy. Aust NZ J Med 1995 25 : 241 242.
4. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000 356 : 608 609.
5. Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005 59 : 233 238.
6. Vleeming W, van Amsterdam JG, Stricker BH, De Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998 18 : 171 188.
7. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002 359 : 2088 2089.
8. Lefebvre J, Murphey LJ, Hartert TV, Jiao SR, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002 39 : 460 464.
9. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, Adam A. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002 303 : 232 237.
10. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002 347 : 621 622.
11. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998 351 : 1693 1697.
12. Sigler C, Annis K, Cooper K, Haber H, Van deCarr S. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol 1997 133 : 972 975.
13. Bas M, Kojda G, Bier H, Hoffmann TK. Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs. Eine Frage der Zeit? HNO 2004 52 : 886 890.
14. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997 59 : 395 412.
15. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994 87 : 567 574.
16. Soubrier F, henc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 1988 85 : 9386 9390.
17. Rigat B, Hubert C, Henc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990 86 : 1343 1346.
18. Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995 25 : 1266 1269.
19. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998 97 : 1411 1420.
20. Bantis C, Heering PJ, Luther Y, Aker S, Kuhr N, Grabensee B, Ivens K. Influence of cytokine gene polymorphisms on focal segmental glomerulosclerosis. Am J Nephrol 2004 24 : 427 431.
21. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004 3 : 845 852.
22. Braun A, Maier E, Kammerer S, Muller B, Roscher AA. A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Hum Genet 1996 97 : 688 689.
23. Burch RM, Kyle DJ. Recent developments in the understanding of bradykinin receptors. Life Sci 1992 50 : 829 838.
24. Braun A, Kammerer S, Bohme E, Muller B, Roscher AA. Identification of polymorphic sites of the human bradykinin B2 receptor gene. Biochem Biophys Res Commun 1995 211 : 234 240.
25. Braun A, Kammerer S, Maier E, Bohme E, Roscher AA. Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 1996 33 : 32 5.
26. Kammerer S, Braun A, Arnold N, Roscher AA. The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region. Biochem Biophys Res Commun 1995 211 : 226 233.
27. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996 60 : 8 13.
28. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999 48 : 861 865.
29. Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 1997 99 : 134 146.
30. van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 2000 35 : 484 490.
31. Seckin D, Ilhan N, Ilhan N, Ozbay Y. The relationship between ACE insertion/deletion polymorphism and coronary artery disease with or without myocardial infarction. Clin Biochem 2006 39 : 50 4.
32. Tsai IJ, Yang YH, Lin YH, Wu VC, Tsau YK, Hsieh FJ. Angiotensin- converting enzyme gene polymorphism in children with idiopathic nephrotic syndrome. Am J Nephrol 2006 26 : 157 162.
33. Brown NJ, Blais C Jr., Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol 1998 32 : 373 377.
34. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996 98 : 283 287.
35. Freiberger T, Vyskocilova M, Kolarova L, Kuklinek P, Krystufkova O, Lahodna M, Hanzlikova J, Litzman J. Exon 1 polymorphism of the B2BKR gene does not influence the clinical status of patients with hereditary angioedema. Hum Immunol 2002 63 : 492 494.
36. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002 16 : 857 863.